Switch to:
More From Other Websites
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards? Feb 23 2017
TESARO Announces Participation at Two Investor Conferences Feb 21 2017
AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
Clovis, Tesaro Soar on Astrazeneca Phase Three News Feb 17 2017
Tesaro downgraded by FBR & Co. Feb 16 2017
Tesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017 Feb 14 2017
Tesaro's Rumored Sale Could Fetch North Of $200 Per Share: Analysts Feb 10 2017
Leerink Cuts Tesaro To Hold After Takeover Speculation Rally Feb 10 2017
Tesaro Explores Possible Sale With Investment Bank Feb 10 2017
Tesaro Rockets To All-Time High On Rumored Takeover Interest Feb 08 2017
Tesaro shares skyrocket on report of buyout interest from drugmakers Feb 08 2017
Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources Feb 08 2017
Tesaro Announces Participation at Two Investor Conferences Feb 02 2017
Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock? Feb 01 2017
Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC... Jan 31 2017
Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool Jan 30 2017
Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 Jan 20 2017
Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer Jan 17 2017
Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference Jan 13 2017
US FDA clears ovarian cancer drug for hard-to-treat disease Dec 19 2016
Tesaro Announces Participation in Three Investor Conferences Nov 21 2016
TESARO Announces Pricing of Public Offering of Common Stock Nov 15 2016
TESARO Announces Proposed Public Offering of Common Stock Nov 14 2016
TESARO Announces Third-Quarter 2016 Operating Results Nov 03 2016
Read this press release » Nov 03 2016
Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent... Nov 01 2016
TESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMA Oct 27 2016
TESARO Announces Participation in Three Investor Conferences Oct 24 2016
Tesaro to Announce Third-Quarter 2016 Financial Results on November 3, 2016 Oct 20 2016
TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results... Oct 08 2016
TESARO and Zai Lab Announce Collaboration, Development and License Agreement Sep 29 2016
TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission Sep 12 2016
TESARO Announces Participation at Four Investor Conferences Aug 24 2016
Read this press release » Aug 04 2016
Tesaro Announces Second-Quarter 2016 Operating Results Aug 04 2016
ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial Jul 08 2016
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Jul 07 2016
TESARO Announces Pricing of Public Offering of Common Stock Jun 30 2016
TESARO Announces Proposed Public Offering of Common Stock Jun 30 2016
TESARO's Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer... Jun 29 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK